Insider Buying: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Acquires $46,500.00 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Rekha Hemrajani acquired 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This represents a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ALX Oncology Stock Down 10.5 %

ALXO opened at $1.62 on Friday. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83. The business’s fifty day simple moving average is $1.52 and its 200 day simple moving average is $4.16.

Institutional Trading of ALX Oncology

Large investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. acquired a new stake in shares of ALX Oncology during the second quarter valued at $1,834,000. California State Teachers Retirement System boosted its stake in shares of ALX Oncology by 413.8% during the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after acquiring an additional 18,360 shares during the last quarter. Marshall Wace LLP boosted its stake in ALX Oncology by 423.0% in the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after buying an additional 514,133 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in ALX Oncology in the 3rd quarter worth about $88,000. Finally, Vanguard Group Inc. boosted its stake in ALX Oncology by 4.3% in the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after buying an additional 64,055 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

Wall Street Analyst Weigh In

ALXO has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. UBS Group dropped their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Stifel Nicolaus restated a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.